Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00425503 · ClinicalTrials.gov registry record · Phase 2

PS-341 Followed by Removal of Prostate for Those With Prostate Cancer

A Phase 2 study of Prostate Neoplasms, sponsored by Baylor College of Medicine.

Completed
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT00425503: Completed Phase 2 study of Prostate Neoplasms, sponsored by Baylor College of Medicine.

NCT00425503 is a Phase 2 study of Prostate Neoplasms that has completed, run by Baylor College of Medicine. The registered enrollment target is 40 participants, below the 141-participant average among 4 other Prostate Neoplasms trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00425503, a Phase 2 study of Prostate Neoplasms, has completed, sponsored by Baylor College of Medicine.

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Following pretreatment evaluation, patients receive PS-341 by intravenous push weekly for 4 consecutive weeks followed by a 24-72 hour rest period. This schedule consists of one treatment cycle. Upon the completion of 4 weeks of PS-341 followed by a 24-72 hour rest period, radical prostatectomy will be performed. Surgery will be delayed if there is any bleeding abnormality (bleeding time greater than 10 minutes) and until platelet count is more than or equal to 100,000 and coagulation profile (PT, PTT) is normal. If at the time of surgery a patient is found to have positive lymph nodes, prostatectomy will be abandoned, the prostate will be biopsied, and the patient will be offered other treatment modalities (hormones, radiation therapy).

Primary Outcome

Pour wound healing is defined in the protocol as dehiscence of fascia during the first postoperative week. Excessive bleeding is defined in the protocol as greater than 2 units of blood required during the first 24 hours after surgery.

Conditions Studied

Interventions

  • DRUG PS-341 (bortezomib)

Study Locations (1)

Texas

  • Scott Department of Urology, Baylor College of Medicine - Houston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2001-12
Est. Completion 2013-12
Phase Phase 2
Baylor College of Medicine

616 total trials

What the finished NCT00425503 record still lists

NCT00425503 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 141-participant average among 4 other Prostate Neoplasms trials with a reported enrollment target (72% lower).

The record links to 1 condition, with Prostate Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which PS-341 (bortezomib) is the first listed.

NCT00425503 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00425503 about?

NCT00425503 is a clinical study titled "PS-341 Followed by Removal of Prostate for Those With Prostate Cancer". Following pretreatment evaluation, patients receive PS-341 by intravenous push weekly for 4 consecutive weeks followed by a 24-72 hour rest period. This schedule consists of one treatment cycle. Upon the completion of 4 weeks of PS-341 followed by a 24-72 hour rest period, radical prostatectomy will...

What is the current status of trial NCT00425503?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2001-12. Estimated completion is 2013-12.

What conditions does trial NCT00425503 study?

This clinical trial studies the following conditions: Prostate Neoplasms.

What interventions are being tested in trial NCT00425503?

The interventions under investigation include: PS-341 (bortezomib) (DRUG).

Who is sponsoring clinical trial NCT00425503?

This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00425503 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00425503, the US trial registry maintained by the National Library of Medicine. NCT00425503 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.